Study of the Inflammation and Airway Changes That Occur After Exposure to Allergen in Asthmatics

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs) that are differentially expressed in the airway epithelium of patients with asthma at baseline and in response to allergen challenge. We hypothesize that allergen exposure enhances airway smooth muscle contractility and epithelial cell mRNA/miRNA production as a consequence of locally increased T-cell derived cytokine production. The study will involve three visits over the course of approximately 14 days. At Visit 1, participants will be characterized in detail with lung function testing, methacholine challenge testing, and allergen skin prick testing. At Visit 2, participants will undergo bronchoscopy with segmental allergen administration of either cat or dust mite standardized allergen extract. At Visit 3 (either 24 hours later or 7 days later), bronchoscopy will be performed to collect airway samples including bronchoalveolar lavage (BAL), epithelial brushings and endobronchial biopsies. Sample analysis will include measurement of miRNA and mRNA expression in epithelial brushings (RNAseq and qPCR); analysis of cell surface markers on BAL cells and blood cells; and collection of endobronchial biopsies for immunostaining of immune cells localization, immunoblotting of smooth cell protein phosphorylation, analysis of mucin content and smooth muscle cell subculture. A total of 38 subjects (26 asthmatics with stable or well-controlled asthma, 6 allergic non-asthmatics and 6 non-allergic non-asthmatics) will complete the study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Role of microRNAs in T Cell-Driven Inflammation in Asthma

NCT01484691

Asthma

COMPLETED NA

Pilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation

NCT00595491

Asthma

RECRUITING PHASE1

Identification of Molecular Biomarkers to Stratify Patients With Refractory Asthma

NCT01589198

Asthma

COMPLETED

T Cell Effector and Regulatory Mechanisms in Asthma

NCT01612936

Asthma Allergies

COMPLETED PHASE1

Measurements of Inflammation Induced by Allergen Inhalation Challenge in Mild Allergic Asthma

NCT06411886

Mild Asthma

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single group before and after administration of allergen

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Allergen challenge subjects

Intervention: Segmental airway allergen challenge

Three types of subjects are studied in this arm:

1\) Volunteers with neither asthma nor allergy (as established by skin prick testing); 2) Volunteers with allergy (as established by skin prick testing) but without asthma; and 3) Volunteers with both asthma and allergy (as established by skin prick testing)

Group Type EXPERIMENTAL

Segmental airway allergen challenge

Intervention Type BIOLOGICAL

Bronchoscopy

Intervention Type PROCEDURE

Methacholine challenge test

Intervention Type DIAGNOSTIC_TEST

Spirometry

Intervention Type DIAGNOSTIC_TEST

Allergen skin prick test

Intervention Type DIAGNOSTIC_TEST

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Segmental airway allergen challenge

Intervention Type BIOLOGICAL

Bronchoscopy

Intervention Type PROCEDURE

Methacholine challenge test

Intervention Type DIAGNOSTIC_TEST

Spirometry

Intervention Type DIAGNOSTIC_TEST

Allergen skin prick test

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Positive skin test to dust mite or cat allergen

Non-Allergic/Non-Asthmatic subjects

* Negative skin test to panel of 12 allergens, including dust mite and cat allergen

All groups

Exclusion Criteria

* History of intubation for asthma exacerbation
* Use of Xolair (omalizumab) within the last 6 months
* Immunotherapy with cat or dust mite extract now or in the past 5 years
* ≥ 10 pack-years smoking or any smoking in the past year
* Other lung diseases, such as sarcoidosis, bronchiectasis or active lung infection
* History of dermatographia
* History of anaphylaxis to cat allergen
* Participation in another research study involving a drug or biologic during the past 30 days
* Presence of past or current medical problems/other factors that may pose additional risks from participation or influence study results, as determined per study investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes